HIV-1 Infection - Pipeline Review, Q4 2010

HIV-1 Infection - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “HIV-1 Infection Pipeline Review, Q4 2010”, provides an overview of the HIV-1 Infection therapeutic pipeline. This report provides information on the therapeutic development for HIV-1 Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV-1 Infection. “HIV-1 Infection-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for HIV-1 Infection.
- A review of the HIV-1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the HIV-1 Infection pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for HIV-1 Infection.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding HIV-1 Infection pipeline depth and focus of HIV-1 Infection therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
HIV-1 Infection Overview
Therapeutics Development
An Overview of Pipeline Products for HIV-1 Infection
HIV-1 Infection Therapeutics under Development by Companies
HIV-1 Infection Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in HIV-1 Infection Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Gilead Sciences, Inc.
United Biomedical, Inc.
Koronis Pharmaceuticals, Inc.
Critical Outcome Technologies Inc.
Samaritan Pharmaceuticals, Inc.
Vironova AB
Cytheris SA
Heat Biologics, Inc.
Kemin Industries, Inc.
ViiV Healthcare
RFS Pharma, LLC
Universities/Institutes Involved in HIV-1 Infection Therapeutics Development
HIV-1 Infection Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Abacavir + Lamivudine + PI + NNRTI - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Abacavir + Lamivudine + Tenofovir + PI/NNRTI - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Atazanavir + Ritonavir + Abacavir / Lamivudine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GS-9350 + Atazanavir + Emtricitabine + Tenofovir DF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Invirase + Emtricitabine/Tenofavir + Ritonavir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Telzir + Norvir + Abacavir + Lamivudine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tenofovir + Abacavir + Lamivudine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Viread + Epivir+ Sustiva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zerit + Epivir + Sustiva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Darunavir + Ritonavir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Efavirenz + Lamivudine + Stavudine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Emtricitabine + Tenofovir Disoproxil Fumarate + Darunavir + Ritonavir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Emtricitabine + Tenofovir Disoproxil Fumarate + Raltegravir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Emtricitabine + Tenofovir Disoproxil Fumarate + Ritonavir + Atazanavir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Isentress + Celsentri + Prezista + Norvir + Truvada - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kaletra1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lopinavir + Ritonavir + Efavirenz - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lopinavir + Ritonavir + Lamivudine + Stavudine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lopinavir + Ritonavir + Lamivudine + Tenofovir Disoproxil Fumarate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lopinavir + Ritonavir + Zidovudine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nevirapine + Zidovudine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zidovudine + Lamivudine + Efavirenz - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
HIV-1 Infection - Featured News
Jul 22, 2010: Tibotec's TMC278 Pivotal Phase III Clinical Trials Achieve Primary Objective
Jul 16, 2009: Tibotec Signs Agreement To Develop And Commercialize Fixed-Dose Combination Of TMC278 And Truvada With Gilead
Jun 12, 2008: Positive Phase I/II Data Of IDX899 Confirm Potent Antiviral Activity And Favorable Safety Profile In Treatment-Naïve HIV-Infected Patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer